A randomized phase 2 study of continuous or intermittent dosing schedule of imatinib re-challenge in patients with tyrosine kinase inhibitor-refractory gastrointestinal stromal tumors.

被引：0
|
作者：
Kim, Hyung-Don
Yoo, Changhoon
Ryu, Min-Hee
Kang, Yoon-Koo
机构：
[1] Univ Ulsan, Dept Oncol, Asan Med Ctr, Coll Med, Seoul, South Korea
[2] Univ Uslan, Asan Med Ctr, Coll Med, Seoul, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
11538
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A multicenter study of the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib plus durvalumab in patients with relapsed/refractory (R/R) solid tumors.
    Hong, David S.
    Rasco, Drew W.
    Veeder, Michael H.
    Luke, Jason J.
    Chandler, Jason
    Balmanoukian, Ani Sarkis
    George, Thomas J.
    Munster, Pamela
    Berlin, Jordan
    Gutierrez, Martin
    Mita, Alain C.
    Wakelee, Heather A.
    Samakoglu, Selda
    Guan, Shanhong
    Dimery, Isaiah W.
    Borazanci, Erkut
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [22] Safety and efficacy of dasatinib in patients with advanced gastrointestinal stromal tumors refractory to imatinib and sunitinib: A single arm, multicenters, phase 2 trial.
    Li, Jian
    Zhou, Ye
    Zhang, Xinhua
    Wu, Xiaojun
    Zhou, Yongjian
    Liu, Xiufeng
    Zhang, Bo
    Wu, Xin
    Lin, Shen
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [23] A first in human phase I study of receptor tyrosine kinase (RTK) inhibitor MGCD516 in patients with advanced solid tumors.
    Bauer, Todd Michael
    Adkins, Douglas
    Schwartz, Gary K.
    Werner, Theresa Louise
    Alva, Ajjai Shivaram
    Hong, David S.
    Carvajal, Richard D.
    Saleh, Mansoor N.
    Bazhenova, Lyudmila
    Goel, Sanjay
    Eaton, Keith D.
    Siegel, Robert D.
    Wang, Ding
    Lauer, Richard C.
    Neuteboom, Saskia T. C.
    Faltaos, Demiana
    Chen, Isan
    Christensen, James
    Chao, Richard C.
    Heist, Rebecca Suk
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [24] A phase II study of the KIT inhibitor XL820 in patients with advanced gastrointestinal stromal tumors (GIST) resistant to or intolerant of imatinib and/or sunitinib
    Wagner, A. J.
    Yazji, S.
    Morgan, J. A.
    Choy, E.
    George, S.
    Hohos, M.
    O'Mara, M.
    Demetri, G. D.
    EJC SUPPLEMENTS, 2008, 6 (12): : 67 - 67
  • [25] A phase Ib study of BGJ398, a pan-FGFR kinase inhibitor in combination with imatinib in patients with advanced gastrointestinal stromal tumor
    Ciara M. Kelly
    Alexander N. Shoushtari
    Li-Xuan Qin
    Sandra P. D’Angelo
    Mark A. Dickson
    Mrinal M. Gounder
    Mary Louise Keohan
    Chloe Mcfadyen
    Ana Sjoberg
    Samuel Singer
    Ronald P. DeMatteo
    Sinchun Hwang
    M. H. Heinemann
    Jasmine H. Francis
    Cristina R. Antonescu
    Ping Chi
    William D. Tap
    Investigational New Drugs, 2019, 37 : 282 - 290
  • [26] A phase Ib study of BGJ398, a pan-FGFR kinase inhibitor in combination with imatinib in patients with advanced gastrointestinal stromal tumor
    Kelly, Ciara M.
    Shoushtari, Alexander N.
    Qin, Li-Xuan
    D'Angelo, Sandra P.
    Dickson, Mark A.
    Gounder, Mrinal M.
    Keohan, Mary Louise
    Mcfadyen, Chloe
    Sjoberg, Ana
    Singer, Samuel
    DeMatteo, Ronald P.
    Hwang, Sinchun
    Heinemann, M. H.
    Francis, Jasmine H.
    Antonescu, Cristina R.
    Chi, Ping
    Tap, William D.
    INVESTIGATIONAL NEW DRUGS, 2019, 37 (02) : 282 - 290
  • [27] A PHASE II STUDY OF DOVITINIB IN PATIENTS WITH METASTATIC OR UNRESECTABLE GASTROINTESTINAL STROMAL TUMORS AFTER FAILURE OF TWO OR MORE TYROSINE KINASE INHIBITORS
    Kang, Y.
    Ryu, M. H.
    Lee, J. J.
    Park, I.
    Park, J. H.
    Ryoo, B.
    ANNALS OF ONCOLOGY, 2012, 23 : 480 - 480
  • [28] Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033
    Blanke, Charles D.
    Rankin, Cathryn
    Demetri, George D.
    Ryan, Christopher W.
    von Mehren, Margaret
    Benjamin, Robert S.
    Raymond, A. Kevin
    Bramwell, Vivien H. C.
    Baker, Laurence H.
    Maki, Robert G.
    Tanaka, Michael
    Hecht, J. Randolph
    Heinrich, Michael C.
    Fletcher, Christopher D. M.
    Crowley, John J.
    Borden, Ernest C.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (04) : 626 - 632
  • [29] S0502: A SWOG Phase III Randomized Study of Imatinib, With or Without Bevacizumab, in Patients With Untreated Metastatic or Unresectable Gastrointestinal Stromal Tumors
    Blanke, Charles D.
    Rankin, Cathy
    Corless, Christopher
    Eary, Janet F.
    Mulder, Karen
    Okuno, Scott H.
    George, Suzanne
    Heinrich, Michael
    ONCOLOGIST, 2015, 20 (12): : 1353 - 1354
  • [30] Analysis of serum protein biomarkers and circulating tumor (ct) DNA for activity of dovitinib in patients (pts) with tyrosine kinase inhibitor (TKI)-refractory gastrointestinal stromal tumors (GIST).
    Yoo, Changhoon
    Ryu, Min-Hee
    Ryoo, Baek-Yeol
    Park, Sook Ryun
    Yoon, Shinkyo
    Na, Young-Soon
    Kang, Yoon-Koo
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345